A randomized, open label, three way crossover relative bioavailability study in healthy adult male and female subjects to evaluate the bioavailability of GRC 4039 (1 mg and 5 mg) following single oral administration of a tablet formulation under fasting and fed conditions compared with that of a capsule in fasting condition.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Revamilast (Primary)
- Indications Multiple sclerosis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Glenmark Pharmaceuticals S.A.
- 08 Feb 2010 New trial record